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Leishmaniasis is a major vector-borne parasitic disease af-
fecting 12 million people worldwide. With a broad range of
clinical manifestations, ranging from self-healing skin ulcers
to disﬁguring mucosal lesions to life-threatening infections
ofvisceralorgans(liverand spleen),the disease hasbecome a
serious human health issue, particularly in developing coun-
tries. Among all of its forms, visceral leishmaniasis (VL, also
known as kala-azar), caused by the Leishmania donovani
complex (i.e., L. donovani and L. infantum in Old World and
L.chagasiinNewWorld),isoftenfatalintheabsenceoftreat-
ment. Although humans are the principal hosts for L. dono-
vani, canine species are the main reservoirs of L. infantum.
Canine VL aﬀects millions of dogs and is associated with
outbreaks of human VL and hence has become a major pub-
lic health issue. The lack of vaccines to prevent and/or treat
these infections, as well as the emergence of drug resistant
parasites, is serious impediments to control leishmaniasis.
Therefore, developing new prophylactic and therapeutic
strategies against this disease is urgently required. However,
for this to occur, a better understanding of the complex
immune mechanisms generated in response to infection and
deﬁning those involved in resistance to infection is required.
In this special issue on “Immunity to visceral leishmaniasis”,
several selected papers will discuss these issues.
The ﬁrst paper in this special issue describes recent ad-
vances in vaccination strategies against VL. To date there is
no vaccine available for any form of human leishmaniasis.
The lack of knowledge relating to disease pathogenesis, the
rise of coinfection with HIV, and cost of development are
signiﬁcant hindrances to vaccine development. Therefore, to
reduce the burden of VL, particularly in resource poor na-
tions, increased investment in VL vaccine development is re-
quired. The second paper in this issue focuses on the util-
ity of live-attenuated parasites as vaccine candidates. Al-
thoughsubunitLeishmaniavaccineshaveshownsomeeﬃca-
cy in animal models, they have not yet been shown to have
protective eﬀects in humans. The recuperation of infected
individualsandsubsequentprotectionfromreinfectionindi-
catesthatinfectionwiththeparasitemaybeaprerequisitefor
the development of protective immunity. Thus, to achieve
long lasting protection, genetically altered live-attenuated
parasites could be a valuable tool. The third paper in this
issue discusses recent advances made in cytokine and pheno-
typic cell proﬁles in diﬀerent tissues and organs of dogs in-
fected with L. infantum. Dogs represent an important reser-
voir of parasites in some regions, and infected dogs have
been linked with human VL cases. This paper describes some
of the complex immune responses developed by the dog in
response to infection. The fourth paper in the issue describes
evasion mechanisms employed by parasites that enable them
to persist within the host. Parasites modulate the host
immune response inthespleenandliverdiﬀerently in mouse
models, as indicated by a distinct pattern of organ-speciﬁc
parasite growth during disease progression. While infection
in the liver resolves within 6–8 weeks, a chronic infection
becomes established in the spleen. Although the exact
immune mechanisms responsible for parasite persistence
in spleen are not known, it is now clear that the parasite2 Journal of Tropical Medicine
plays an important role in this process. The ﬁfth paper
in the issue describes novel immune evasion mechanisms
employed by the Leishmania parasite, and in particularly,
those used by virulent promastigote and amastigote forms
that overexpress a glycoprotein enzyme (ectonucleotidase)
on the parasite plasma membrane. The ectonculeotidase,
with its catalytic sites facing extracellularly, hydrolyses extra-
cellular nucleotides resulting in the production of adenosine.
Increased levels of adenosine aid in the establishment of
infection. Thus, the discovery of the immunomodulatory
eﬀects of adenosine and the characterisation of ectonucleoti-
dases provide new insights into complex immune responses
during leishmaniasis. The ﬁnal paper in this issue dis-
cusses Leishmania-mediated manipulation of the signalling
machinery of the host cell that enables parasite persistence.
The identiﬁcation of the key signalling mechanisms modu-
lated by parasites will help to understand the strategies used
by parasites to subvert the host immune system. Moreover,
given that these signalling pathways could be manipulated
pharmacologically, an improved understanding of the host-
parasite interaction may allow the development of new
therapies to control leishmaniasis.
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